LACTULOSUM 667 mg /Ml Syrup

Contents of the leaflet

1. ARTICLE 1. PURPOSE
   1. ARTICLE 2. DEFINITIONS
   2. ARTICLE 3. SERVICES
   3. ARTICLE 4. COMPENSATION
   4. ARTICLE 5. TERM AND TERMINATION
   5. ARTICLE 6. CONFIDENTIALITY
   6. ARTICLE 7. INTELLECTUAL PROPERTY
   7. ARTICLE 8. GOVERNING LAW
   8. ARTICLE 9. ENTIRE AGREEMENT
   9. ARTICLE 10. AMENDMENTS
   10. ARTICLE 11. NOTICES
   11. ARTICLE 12. ASSIGNMENT
   12. ARTICLE 13. FORCE MAJEURE
   13. ARTICLE 14. DISPUTE RESOLUTION
   14. ARTICLE 15. SEVERABILITY
   15. ARTICLE 16. COUNTERPARTS
   16. ARTICLE 17. WAIVER
   17. ARTICLE 18. HEADINGS
   18. Leaflet attached to the packaging: patient information
   19. Table of contents of the leaflet
2. What is Lactulosum Orifarm Forte and what is it used for
3. Important information before taking Lactulosum Orifarm Forte
4. How to take Lactulosum Orifarm Forte
5. Possible side effects
6. How to store Lactulosum Orifarm Forte
7. Contents of the pack and other information
   1. ARTICLE 1. PURPOSE
   2. ARTICLE 2. DEFINITIONS
   3. ARTICLE 3. SERVICES
   4. ARTICLE 4. COMPENSATION
   5. ARTICLE 5. CONFIDENTIALITY
   6. ARTICLE 6. TERM AND TERMINATION
   7. ARTICLE 7. GOVERNING LAW
   8. ARTICLE 8. ENTIRE AGREEMENT
   9. ARTICLE 9. AMENDMENTS
   10. ARTICLE 10. NOTICES
   11. Lactulosum Orifarm Forte
   12. Dosage Adults and children over 12 years:
   14. How to take Lactulosum Orifarm Forte
   15. ARTICLE I. NAME
   16. ARTICLE II. PURPOSE
   17. ARTICLE III. MEMBERSHIP
   18. ARTICLE IV. DUES
   19. ARTICLE V. BOARD OF DIRECTORS
   20. ARTICLE VI. OFFICERS
   21. ARTICLE VII. AMENDMENTS
   22. In case of taking a larger dose of the medicine than recommended, consult a doctor or pharmacist
   23. Missing a dose of Lactulosum Orifarm Forte
   24. In case of any further doubts about taking this medicine, consult a doctor or pharmacist.
   25. Reporting side effects
   26. Storage of Lactulosum Orifarm Forte
   27. Expiration date of Lactulosum Orifarm Forte
   28. What Lactulosum Orifarm Forte contains
   29. Packaging of Lactulosum Orifarm Forte
   30. Marketing Authorization Holder of Lactulosum Orifarm Forte
8. ARTICLE I. NAME
9. ARTICLE II. PURPOSE
10. ARTICLE III. MEMBERSHIP
11. ARTICLE IV. DUES
12. ARTICLE V. OFFICERS
13. ARTICLE VI. BOARD OF DIRECTORS
14. ARTICLE VII. ELECTIONS
15. ARTICLE VIII. MEETINGS
16. ARTICLE IX. AMENDMENTS
17. ARTICLE X. PARLIAMENTARY AUTHORITY
18. ARTICLE I. Name and Organization
19. ARTICLE II. Objectives
20. ARTICLE III. Membership
21. ARTICLE IV. Board of Directors
22. ARTICLE V. Officers
23. ARTICLE VI. Committees
24. ARTICLE VII. Amendments
    1. Appendix No. 1 to the Regulation No. 76/2023/DSO
    2. List of streets covered by the Szczecin City Center Protection Zone
    3. ARTICLE 1. - DEFINITIONS
    4. ARTICLE 2. - ZONING DISTRICTS
    5. ARTICLE 3. - R-1 RESIDENTIAL DISTRICT
    6. ARTICLE 4. - R-2 RESIDENTIAL DISTRICT
    7. ARTICLE 5. - R-3 RESIDENTIAL DISTRICT
    8. ARTICLE 6. - B-1 BUSINESS DISTRICT
    9. ARTICLE 7. - I-1 INDUSTRIAL DISTRICT
25. How to store the medicine Lactulosum Forte
26. Package contents and other information
    1. INSTRUCTIONS FOR USE DEXAMETHASONE 0.1%

ARTICLE 1. PURPOSE

The purpose of this Agreement is to set forth the terms and conditions under which Sellershall provide certain Servicesto Buyer, as described in Exhibit A, and Buyershall pay Sellerfor such Services.

ARTICLE 2. DEFINITIONS

As used in this Agreement, the following terms shall have the meanings set forth below:

• “Agreement” means this Agreement, including all exhibits and schedules attached hereto.
• “Buyer” means [Company Name], a [State]corporation with its principal place of business at [Address].
• “Confidential Information” means any information disclosed by one party to the other party, whether orally or in writing, that is designated as confidential or that reasonably should be understood to be confidential given the nature of the information and the circumstances of its disclosure.
• “Deliverables” means the tangible and intangible outputs of the Servicesprovided by Sellerto Buyer, as described in Exhibit A.
• “Effective Date” means the date on which this Agreement is executed by both parties.
• “Services” means the services to be provided by Sellerto Buyeras described in Exhibit A.
• “Seller” means [Company Name], a [State]corporation with its principal place of business at [Address].

ARTICLE 3. SERVICES

Sellershall provide the Servicesto Buyerin accordance with the terms and conditions of this Agreement and the specifications set forth in Exhibit A. Sellershall perform the Servicesin a professional and workmanlike manner, using qualified personnel and in compliance with all applicable laws and regulations.

ARTICLE 4. COMPENSATION

In consideration for the Servicesprovided by Seller, Buyershall pay Sellerthe fees set forth in Exhibit B. Payment shall be made within [Number]days of receipt of Seller’s invoice.

ARTICLE 5. TERM AND TERMINATION

This Agreement shall commence on the Effective Dateand shall continue for a term of [Number]years, unless earlier terminated as provided herein. Either party may terminate this Agreement upon [Number]days’ written notice to the other party if the other party materially breaches this Agreement and fails to cure such breach within [Number]days of receiving written notice thereof.

ARTICLE 6. CONFIDENTIALITY

Each party agrees to hold the other party’s Confidential Informationin strict confidence and to not disclose such information to any third party without the other party’s prior written consent. This obligation shall survive the termination of this Agreement.

ARTICLE 7. INTELLECTUAL PROPERTY

Any intellectual property created by Sellerin the course of providing the Servicesshall be owned by [Owner]. Sellerhereby assigns to [Owner]all right, title, and interest in and to such intellectual property.

ARTICLE 8. GOVERNING LAW

This Agreement shall be governed by and construed in accordance with the laws of the State of [State].

ARTICLE 9. ENTIRE AGREEMENT

This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior or contemporaneous communications and proposals, whether oral or written.

ARTICLE 10. AMENDMENTS

This Agreement may be amended only by a written instrument signed by both parties.

ARTICLE 11. NOTICES

All notices required or permitted under this Agreement shall be in writing and shall be delivered by certified mail, return receipt requested, to the addresses set forth above.

ARTICLE 12. ASSIGNMENT

This Agreement may not be assigned by either party without the prior written consent of the other party.

ARTICLE 13. FORCE MAJEURE

Neither party shall be liable for any delay or failure to perform its obligations under this Agreement if such delay or failure is caused by events beyond its reasonable control, including but not limited to acts of God, war, terrorism, natural disasters, and government regulations.

ARTICLE 14. DISPUTE RESOLUTION

Any dispute arising out of or relating to this Agreement shall be settled by [Method]in [Location].

ARTICLE 15. SEVERABILITY

If any provision of this Agreement is held to be invalid or unenforceable, such provision shall be struck from this Agreement and the remaining provisions shall remain in full force and effect.

ARTICLE 16. COUNTERPARTS

This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

ARTICLE 17. WAIVER

No waiver of any provision of this Agreement shall be deemed a waiver of any other provision or of the same provision on a future occasion.

ARTICLE 18. HEADINGS

The headings used in this Agreement are for convenience only and shall not be used to interpret the meaning of any provision of this Agreement.

Leaflet attached to the packaging: patient information

Lactulosum Orifarm Forte, 667 mg/ml, syrup
Lactulosum
Before taking the medicine, carefully read the contents of the leaflet, as it contains important information for the patient.
This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist.
Keep this leaflet, you may need to read it again.
If you need advice or additional information, consult a pharmacist.
If the patient experiences any side effects, including any possible side effects not listed in the leaflet, they should inform their doctor or pharmacist.
See section 4.
If, after taking one package of the medicine, there is no improvement or the patient feels worse, they should contact their doctor (this does not apply to chronic constipation).

Table of contents of the leaflet

1. What is Lactulosum Orifarm Forte and what is it used for
2. Important information before taking Lactulosum Orifarm Forte
3. How to take Lactulosum Orifarm Forte
4. Possible side effects
5. How to store Lactulosum Orifarm Forte
6. Contents of the pack and other information

1. What is Lactulosum Orifarm Forte and what is it used for

Lactulose is a synthetic disaccharide that, when administered orally, is not broken down by digestive enzymes and is practically not absorbed from the gastrointestinal tract. In the large intestine, lactulose is broken down by bacteria into organic acids, mainly lactic acid, which leads to acidification of the large intestine contents. The products of lactulose breakdown increase the volume of the intestine contents, stimulate peristalsis, and have a laxative effect.
Lactulose reduces the blood ammonia levels in patients with liver failure in a pre-coma or coma state (hepatic encephalopathy).

2. Important information before taking Lactulosum Orifarm Forte

Lactulosum Orifarm Forte should only be used in the following cases:

• for the treatment of episodic constipation,
• for the treatment of chronic constipation,
• for hepatic encephalopathy (as an auxiliary measure in pre-coma and coma states).

3. How to take Lactulosum Orifarm Forte

This medicine should be taken as directed by a doctor or pharmacist. In case of doubts, consult a doctor or pharmacist.
Dosage
The dosage is determined individually by the doctor, depending on the patient's condition and response to treatment.

• Constipation:Adults and children over 12 years: usually 15-45 ml (1-3 tablespoons) per day.
• Hepatic encephalopathy:Initially 30-45 ml (2-3 tablespoons) every 6-8 hours, and then the maintenance dose is determined individually by the doctor.

The medicine can be taken directly or diluted in a glass of water.
In case of a missed dose, take the next dose as scheduled. Do not take a double dose to make up for a missed dose.
Do not take doses larger than recommended.

4. Possible side effects

Like all medicines, Lactulosum Orifarm Forte can cause side effects, although not everybody gets them.

• Common (may affect up to 1 in 10 people): bloating, abdominal discomfort, diarrhea.
• Uncommon (may affect up to 1 in 100 people): nausea, vomiting.
• Rare (may affect up to 1 in 1000 people): electrolyte disturbances (e.g., potassium deficiency), dehydration.

In case of severe or persistent side effects, consult a doctor.

5. How to store Lactulosum Orifarm Forte

Store at room temperature (up to 25°C). Protect from light and moisture.
Store in a place inaccessible to children.
Do not use after the expiration date stated on the packaging.

6. Contents of the pack and other information

What Lactulosum Orifarm Forte contains:
The active substance is lactulose. 667 mg/ml.
Other ingredients are: purified water, citric acid, strawberry flavor.
What Lactulosum Orifarm Forte looks like and what the pack contains:
Lactulosum Orifarm Forte is a syrup with a color from colorless to light yellow. The medicine is available in plastic bottles of 200 ml or 500 ml.
Marketing Authorisation Holder:
Orifarm Generics A/S
Manufacturer:
Orifarm Generics A/S
Date of last revision of the leaflet: 2018-07-19

ARTICLE 1. PURPOSE

The purpose of this Agreement is to set forth the terms and conditions under which Sellershall provide certain Servicesto Buyer, and Buyershall pay Sellerfor such Services.

ARTICLE 2. DEFINITIONS

As used in this Agreement, the following terms shall have the meanings set forth below:

• “Agreement” means this Agreement, including all exhibits and schedules attached hereto.
• “Buyer” means [Company Name], a [State]corporation with its principal place of business at [Address].
• “Confidential Information” means any and all information disclosed by one party to the other party, whether orally or in writing, that is designated as confidential or that would reasonably be understood to be confidential.
• “Effective Date” means the date on which this Agreement is executed by both parties.
• “Services” means the services described in Exhibit Aattached hereto.
• “Seller” means [Company Name], a [State]corporation with its principal place of business at [Address].

ARTICLE 3. SERVICES

Sellershall provide the Servicesto Buyerin accordance with the terms and conditions of this Agreement and Exhibit A. Sellershall perform the Servicesin a professional and workmanlike manner, and shall comply with all applicable laws and regulations.

ARTICLE 4. COMPENSATION

Buyershall pay Sellerfor the Servicesin the amount set forth in Exhibit Battached hereto. Payment shall be made within [Number]days of receipt of Seller’sinvoice.

ARTICLE 5. CONFIDENTIALITY

Each party agrees to hold the other party’s Confidential Informationin strict confidence, and shall not disclose such information to any third party without the other party’s prior written consent. This obligation shall survive the termination of this Agreement.

ARTICLE 6. TERM AND TERMINATION

This Agreement shall be effective as of the Effective Dateand shall continue in effect for a term of [Number]years, unless terminated earlier as provided herein. Either party may terminate this Agreement upon [Number]days’ written notice to the other party.

ARTICLE 7. GOVERNING LAW

This Agreement shall be governed by and construed in accordance with the laws of the State of [State].

ARTICLE 8. ENTIRE AGREEMENT

This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof, and supersedes all prior or contemporaneous communications and proposals, whether oral or written.

ARTICLE 9. AMENDMENTS

This Agreement may be amended only by a written instrument signed by both parties.

ARTICLE 10. NOTICES

All notices required or permitted under this Agreement shall be in writing and shall be delivered by certified mail, return receipt requested, to the addresses set forth above.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.
[Company Name]
By: _______________________________
Name: _______________________________
Title: _______________________________
[Company Name]
By: _______________________________
Name: _______________________________
Title: _______________________________

Lactulosum Orifarm Forte

Before taking Lactulosum Orifarm Forte, consult a doctor or pharmacist if:the patient suffers from any diseases, in particular:

• the patient has abdominal pain of unknown cause;
• the patient has gastrocardiac syndrome, i.e., Roemheld syndrome (a condition in which accumulated gas in the digestive tract or disturbances in normal gastric passage cause cardiac symptoms);
• the patient does not tolerate milk sugar (lactose);
• the patient has diabetes.

The medicine should not be used in patients with rare hereditary galactose intolerance or fructose intolerance, lactase deficiency (Lapp type), or glucose-galactose malabsorption syndrome.
During long-term use of high doses of lactulose in hepatic encephalopathy, sodium and potassium levels in serum should be monitored.
Patients with gastrocardiac syndrome: if the patient has bloating and gas after taking the medicine, treatment should be discontinued and a doctor consulted.
Chronic use of an inappropriate dose (more than 2-3 bowel movements per day) or improper use can lead to diarrhea and electrolyte imbalance. The medicine should not be used for more than two weeks without consulting a doctor.
During the use of laxative medicines, it is recommended to drink an adequate amount of fluids (about 1.5-2 liters per day, i.e., 6-8 glasses).
In case of no improvement or worsening of symptoms after a few days of taking Lactulosum Orifarm Forte, a doctor should be consulted.
Lactulosum Orifarm Forte and other medicines
Inform a doctor or pharmacist about all medicines currently being taken or recently taken, as well as any medicines planned to be taken.
Since lactulose lowers the pH in the colon, medicines whose release depends on pH may be inactivated.
Lactulosum Orifarm Forte contains:lactulose. Patients with lactose intolerance should note that the medicine contains small amounts of lactose.

Dosage Adults and children over 12 years:

• Initially: 15-30 ml (1-2 tablespoons) twice a day.
• Maintenance dose: 10-25 ml (2/3 - 1 2/3 tablespoons) 1-2 times a day.

Children from 6 to 12 years:

• Initially: 5-10 ml (1/3 - 2/3 tablespoon) twice a day.
• Maintenance dose: 5-15 ml (1/3 - 1 tablespoon) 1-2 times a day.

Children from 1 to 6 years:

• Initially: 2.5-5 ml (1/4 - 1/2 teaspoon) twice a day.
• Maintenance dose: 2.5-10 ml (1/4 - 1 teaspoon) 1-2 times a day.

Infants and young children (under 1 year):

• 0.5-1 ml per kg of body weight twice a day.

The medicine should be taken in the morning, on an empty stomach, or between meals.
In case of a missed dose, take the next dose at the usual time. Do not take a double dose to make up for a missed dose.
In case of doubts, consult a doctor or pharmacist.

p ly p
p zq
p three ja
p j
v p ly p j a y
y a v. p pq wy pq q j
p

How to take Lactulosum Orifarm Forte

This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist. In case of doubts, consult a doctor or pharmacist.
15 ml of the syrup contains 10.0 g of lactulose, and 5 ml of the syrup contains 3.3 g of lactulose.
The dosage should be adjusted individually.
If a single daily dose is taken, it should be taken at the same time, e.g., during breakfast. During the use of laxative medicines, it is recommended to drink an adequate amount of fluids (about 1.5-2 liters, i.e., 6-8 glasses) throughout the day.
Dosing in chronic constipation:
The medicine can be taken in a single daily dose or in two divided doses.
After a few days, the initial dose may be adjusted to a maintenance dose based on the response to treatment. The therapeutic effect may occur after a few days (2-3 days) of treatment.
Adults and adolescents
15-45 ml (10.0 - 30.0 g lactulose)
Children
7-14 years
5-10 ml (3.3 - 6.7 g lactulose)
1-6 years
Infants
up to 5 ml (up to 3.3 g lactulose)
under 1 year
Daily dose
15-30 ml (10.0 - 20.0 g lactulose)
5-10 ml (3.3 - 6.7 g lactulose)
up to 5 ml (up to 3.3 g lactulose)
Older adults and patients with renal impairment and liver disease
There are no special dosage recommendations due to minimal systemic exposure to lactulose.
Dosing in hepatic encephalopathy:
Initial dose: 3-4 times a day 15 ml. The dose should be determined individually to achieve 2-3 bowel movements per day.
For constipation:
10-15 ml per day. The dose should be determined individually to achieve 1-2 bowel movements per day.
Method of administration:
The medicine should be taken orally.
If symptoms do not improve after 7 days of taking the medicine, consult a doctor.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

• In the initial treatment period, gas, bloating, abdominal cramps, and diarrhea may occur.
• Long-term use of high doses may lead to electrolyte loss (especially potassium).

If any side effects occur, discontinue the medicine and consult a doctor.

ARTICLE I. NAME

The name of this organization shall be the National Association of College and University Food Services, Inc., hereinafter referred to as NACUFS.

ARTICLE II. PURPOSE

The purpose of this organization shall be to foster and promote the advancement of food service and nutrition programs in institutions of higher education.

ARTICLE III. MEMBERSHIP

Membership in NACUFS shall be open to institutions of higher education, and to individuals associated with such institutions, who are engaged in the operation of food service programs.

• Institutional Membershipshall consist of colleges and universities which provide food service to their students, faculty, and staff.
• Individual Membershipshall consist of persons employed by or associated with institutions of higher education who are actively engaged in the operation of food service programs.

ARTICLE IV. DUES

The amount of annual dues shall be determined by the Board of Directors and shall be subject to approval by the membership at the annual business meeting.

ARTICLE V. BOARD OF DIRECTORS

The Board of Directors shall consist of nine (9) members elected by the membership. The Board shall be responsible for the overall management and direction of the organization.

1. The Board shall meet at least twice each year.
2. The Board shall have the authority to establish committees as needed.
3. The Board shall be responsible for the financial management of the organization.

ARTICLE VI. OFFICERS

The officers of the organization shall be a President, Vice President, Secretary, and Treasurer. These officers shall be elected by the Board of Directors from among its members.

ARTICLE VII. AMENDMENTS

These Bylaws may be amended by a two-thirds (2/3) vote of the membership at the annual business meeting.

In case of taking a larger dose of the medicine than recommended, consult a doctor or pharmacist

After an overdose, diarrhea, significant fluid loss, decreased potassium levels, and increased sodium levels in the blood are observed.

Missing a dose of Lactulosum Orifarm Forte

If the medicine is taken regularly and it has not been long since the missed dose, take it as soon as possible.
If it is close to the time for the next scheduled dose, take it at the scheduled time. Do not take a double dose to make up for a missed dose.

In case of any further doubts about taking this medicine, consult a doctor or pharmacist.

1. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
Adverse reactions have been reported with an unknown frequency - the frequency cannot be estimated from the available data: allergic reactions, rash, itching, hives.
The frequency of possible adverse reactions listed below is as follows:

• unknown - the frequency cannot be estimated from the available data.

During the use of lactulose as a laxative in constipation, the following adverse reactions have been observed, especially in the initial treatment period:

• mild, transient bloating, abdominal pain, occasionally nausea.
• Rarely, diarrhea has been observed, which resolved after the first 5 hours of treatment.

During the use of lactulose in high doses in hepatic encephalopathy, the following adverse reactions have been observed:

• bloating, abdominal pain, nausea, diarrhea;
• isolated cases of intestinal gas cysts.

Metabolism and nutrition disorders:

• decreased potassium and sodium levels in the blood below normal (hypokalemia);
• increased ammonia levels.

Reporting side effects

If side effects occur, report them to a doctor or pharmacist, or report them directly to the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products.
Reporting side effects allows for the collection of information on the safety of the medicine.

Storage of Lactulosum Orifarm Forte

Store at room temperature, in a dry and dark place.
The medicine should be stored in a place inaccessible to children.

Expiration date of Lactulosum Orifarm Forte

Do not use the medicine after the expiration date stated on the packaging.
Check the expiration date on the bottle label.

What Lactulosum Orifarm Forte contains

The active substance is lactulose. 100 ml of the solution contains 66.7 g of lactulose.
Other ingredients are: purified water, citric acid, strawberry flavor.

Packaging of Lactulosum Orifarm Forte

Lactulosum Orifarm Forte is available in bottles containing 200 ml, 500 ml, and 1000 ml of the solution.

Marketing Authorization Holder of Lactulosum Orifarm Forte

Orifarm Generics sp. z o.o., ul. Stanisława Żółkiewskiego 12, 01-801 Warszawa

ARTICLE I. NAME

This organization shall be known as the National Association of Parliamentarians.

ARTICLE II. PURPOSE

The purpose of this Association shall be to promote parliamentary procedureand to assist its members in becoming proficient in its practice.

ARTICLE III. MEMBERSHIP

Membership in this Association shall be open to all persons interested in parliamentary procedure.

ARTICLE IV. DUES

The amount of annual dues shall be fixed by the Board of Directors.

ARTICLE V. OFFICERS

The officers of this Association shall be a President, Vice-President, Secretary, and Treasurer.

ARTICLE VI. BOARD OF DIRECTORS

The Board of Directors shall consist of the officers of the Association and three other members elected by the membership.

ARTICLE VII. ELECTIONS

Elections shall be held annually.

ARTICLE VIII. MEETINGS

The Association shall hold at least one meeting annually.

ARTICLE IX. AMENDMENTS

These Bylaws may be amended by a two-thirds vote of the membership.

ARTICLE X. PARLIAMENTARY AUTHORITY

Robert’s Rules of Order Newly Revisedshall be the parliamentary authority of this Association.

ARTICLE I. Name and Organization

This organization shall be known as the National Association of Retail Food Stores. It shall be a non-profit corporation organized under the laws of the State of Delaware.

ARTICLE II. Objectives

The objectives of this Association shall be to promote the growth and success of the retail food industry, to serve as a voice for its members, and to provide them with the resources and support they need to thrive. Specifically, the Association shall:

• Represent the interests of its members before government bodies and the public.
• Provide educational programs and resources to help members improve their operations.
• Facilitate the exchange of information and best practices among members.
• Promote the retail food industry to consumers.
• Conduct research and analysis on issues affecting the industry.

ARTICLE III. Membership

Membership in the Association shall be open to any individual, firm, corporation, or other entity engaged in the retail food industry. Membership shall be classified as follows:

1. Retail Members: Those actively engaged in the operation of retail food stores.
2. Associate Members: Those providing products or services to the retail food industry.
3. Honorary Members: Individuals recognized for their outstanding contributions to the industry.

The Board of Directors shall have the authority to establish and modify membership requirements and dues.

ARTICLE IV. Board of Directors

The business and affairs of the Association shall be managed by a Board of Directors. The Board shall consist of fifteen (15) directors, elected by the membership. The terms of the directors shall be three (3) years, with five (5) directorselected each year.
The Board shall meet at least four (4) times per year, and shall have the authority to transact all business necessary to carry out the objectives of the Association.

ARTICLE V. Officers

The officers of the Association shall be a Chairman, a Vice Chairman, a Secretary, and a Treasurer. These officers shall be elected by the Board of Directors from among its members.
The officers shall have the following duties:

• Chairman: Preside over meetings of the Board and the Association, and provide leadership for the organization.
• Vice Chairman: Assist the Chairman and assume their duties in their absence.
• Secretary: Keep the minutes of meetings and maintain the records of the Association.
• Treasurer: Manage the finances of the Association and prepare financial reports.

ARTICLE VI. Committees

The Board of Directors may establish committees to assist in carrying out the objectives of the Association. The committees shall be composed of members of the Association and shall report to the Board.

ARTICLE VII. Amendments

These Bylaws may be amended by a two-thirds (2/3) voteof the Board of Directors, subject to ratification by a majority voteof the membership.

Appendix No. 1 to the Regulation No. 76/2023/DSO

President of the City of Szczecinof June 27, 2023.

List of streets covered by the Szczecin City Center Protection Zone

• Aleja Piastów Street
• Bolesława Krzywoustego Street
• Brama Portowa Street
• Chrobrego Street
• Czysta Street
• Dworcowa Street
• Feliksa Nowowiejskiego Street
• Gałczyńskiego Street
• Hery Street
• Jasna Street
• Jagiellońska Street
• Kaszubska Street
• Kościuszki Street
• Krupnicza Street
• Lutosławskiego Street
• Małkowskiego Street
• Marii Skłodowskiej-Curie Street
• Monte Cassino Street
• Narwicka Street
• Piastowska Street
• Pl. Andersa Street
• Pl. Batorego Street
• Pl. Wolności Street
• Polańskiego Street
• Powstańców Narodowych Street
• Rayskiego Street
• Sienkiewicza Street
• Staromłyńska Street
• Stolarska Street
• Szarotki Street
• Ściegiennego Street
• Teatralna Street
• Wały Chrobrego Street
• Władysława Andersa Street
• Wybickiego Street
• Żółkiewskiego Street

Note:The list of streets may change.

ARTICLE 1. - DEFINITIONS

For the purpose of this chapter, the following terms shall have the meanings indicated:

• “Board”means the City Planning Board of the City of Peekskill.
• “Building”means any structure having a roof and walls and intended for shelter, habitation, or enclosure of any person, animal, equipment, or commodity.
• “Certificate of Occupancy”means a certificate issued by the City of Peekskill, Building Inspector, certifying that a building or part thereof is safe and suitable for occupancy.
• “City”means the City of Peekskill, New York.
• “District”means an area of the City designated on the Zoning Map.
• “Dwelling”means any building or portion thereof designed or used for residential purposes.
• “Family”means an individual, or two or more persons related by blood, marriage, or adoption, living together as a single housekeeping unit; or any number of persons, not related by blood, marriage, or adoption, living together as a single housekeeping unit.
• “Floor Area”means the total area of all floors within the exterior walls of a building or structure, excluding unfinished attics and basements.
• “Height of Building”means the vertical distance from the average finished grade to the highest point of the roof.
• “Lot”means a parcel of land having frontage on a public street.
• “Lot Area”means the total area of a lot.
• “Lot Coverage”means the percentage of the lot area covered by buildings.
• “Nonconforming Use”means a use which lawfully existed prior to the enactment of this chapter, but which does not conform to the provisions hereof.
• “Principal Building”means the main building on a lot.
• “Public Street”means any street which is publicly maintained.
• “Setback”means the minimum horizontal distance required between a building and a property line.
• “Sign”means any device, structure, or part thereof, used to identify, advertise, or direct attention to a person, firm, business, or location.
• “Zoning Map”means the map designating the zoning districts of the City of Peekskill, which is hereby made a part of this chapter.

ARTICLE 2. - ZONING DISTRICTS

The City of Peekskill is hereby divided into the following zoning districts:

1. R-1 Residential District
2. R-2 Residential District
3. R-3 Residential District
4. B-1 Business District
5. I-1 Industrial District

The boundaries of these districts are shown on the Zoning Map.

ARTICLE 3. - R-1 RESIDENTIAL DISTRICT

The R-1 Residential District is intended to provide for single-family dwellings in a low-density residential environment.

• Permitted Uses:
• Single-family dwellings
• Accessory buildings and uses customarily incidental to single-family dwellings
• Home occupations as defined in Article 8
• Lot Size:The minimum lot size shall be 10,000 square feet.
• Lot Width:The minimum lot width shall be 80 feet.
• Lot Coverage:The maximum lot coverage shall be 25%.
• Setbacks:
• Front setback: 30 feet
• Side setback: 15 feet
• Rear setback: 25 feet
• Height of Building:The maximum height of a building shall be 35 feet.

ARTICLE 4. - R-2 RESIDENTIAL DISTRICT

The R-2 Residential District is intended to provide for single-family and two-family dwellings in a moderate-density residential environment.

• Permitted Uses:
• Single-family dwellings
• Two-family dwellings
• Accessory buildings and uses customarily incidental to single-family and two-family dwellings
• Home occupations as defined in Article 8
• Lot Size:The minimum lot size shall be 8,000 square feet.
• Lot Width:The minimum lot width shall be 60 feet.
• Lot Coverage:The maximum lot coverage shall be 30%.
• Setbacks:
• Front setback: 25 feet
• Side setback: 10 feet
• Rear setback: 20 feet
• Height of Building:The maximum height of a building shall be 30 feet.

ARTICLE 5. - R-3 RESIDENTIAL DISTRICT

The R-3 Residential District is intended to provide for multi-family dwellings and other residential uses in a high-density residential environment.

• Permitted Uses:
• Single-family dwellings
• Two-family dwellings
• Multi-family dwellings
• Accessory buildings and uses customarily incidental to residential uses
• Home occupations as defined in Article 8
• Lot Size:The minimum lot size shall be 6,000 square feet.
• Lot Width:The minimum lot width shall be 50 feet.
• Lot Coverage:The maximum lot coverage shall be 40%.
• Setbacks:
• Front setback: 20 feet
• Side setback: 5 feet
• Rear setback: 15 feet
• Height of Building:The maximum height of a building shall be 40 feet.

ARTICLE 6. - B-1 BUSINESS DISTRICT

The B-1 Business District is intended to provide for a variety of retail and service businesses.

• Permitted Uses:
• Retail stores
• Service businesses
• Offices
• Restaurants
• Accessory buildings and uses customarily incidental to the above uses
• Lot Size:There is no minimum lot size.
• Lot Width:There is no minimum lot width.
• Lot Coverage:The maximum lot coverage shall be 75%.
• Setbacks:
• Front setback: 10 feet
• Side setback: 5 feet
• Rear setback: 10 feet
• Height of Building:The maximum height of a building shall be 50 feet.

ARTICLE 7. - I-1 INDUSTRIAL DISTRICT

The I-1 Industrial District is intended to provide for a variety of industrial uses.

• Permitted Uses:
• Manufacturing
• Warehousing
• Distribution
• Accessory buildings and uses customarily incidental to the above uses
• Lot Size:The minimum lot size shall be 1 acre.
• Lot Width:The minimum lot width shall be 100 feet.
• Lot Coverage:The maximum lot coverage shall be 60%.
• Setbacks:
• Front setback: 20 feet
• Side setback: 10 feet
• Rear setback: 20 feet
• Height of Building:The maximum height of a building shall be 60 feet.

5. How to store the medicine Lactulosum Forte

Store at a temperature below 25°C.
The medicine should be stored in a place that is invisible and inaccessible to children.
After the first opening of the bottle, the medicine should not be stored for more than 1 month.
Do not use this medicine after the expiration date stated on the packaging and label. The expiration date indicates the last day of the given month.
Medicines should not be disposed of in the sewage system or household waste containers. You should ask your pharmacist how to dispose of unused medicines. This will help protect the environment.

6. Package contents and other information

What does the medicine Lactulosum Orifarm Forte contain
The active substance of the medicine is lactulose (in the form of liquid lactulose). 1 ml of syrup contains 667 mg of lactulose.
Other ingredients are: purified water.
What does the medicine Lactulosum Orifarm Forte look like and what does the packaging contain
Lactulosum Orifarm Forte is a clear, viscous, colorless or light brown-yellow syrup.
Packaging: a brown glass bottle with a polyethylene (HDPE) screw cap with a guarantee ring and a polyethylene (LDPE, HDPE) flow restrictor (sealing plug). A measuring cup made of polypropylene is attached to the packaging. The bottle contains 150 ml of syrup.
Responsible entity:
Orifarm Healthcare A/S
Energivej 15
5260 Odense S
Denmark
To obtain more detailed information about this medicine, please contact the local representative of the responsible entity:
Orifarm Healthcare Sp. z o.o.
ul. Prądkopowa 31
01-204 Warsaw
Poland
Manufacturer:
Orifarm Manufacturing Poland Sp. z o.o.
ul. Księstwa Łowickiego 12
99-420 Łyszkowice
Poland
Date of the last update of the leaflet: 07/2023

INSTRUCTIONS FOR USE DEXAMETHASONE 0.1%

Ophthalmic Suspension
COMPOSITION
1 ml contains:

• Dexamethasone 0.1 mg
• Benzalkonium chloride 0.01 mg

Excipients: hypromellose, disodium phosphate, sodium phosphate, sodium chloride, purified water.
PHARMACEUTICAL FORM
Ophthalmic suspension.
THERAPEUTIC INDICATIONS
Dexamethasone 0.1% ophthalmic suspension is indicated for the treatment of:

• Steroid-responsive inflammatory conditions of the cornea, conjunctiva, sclera and eyelids.
• Allergic conjunctivitis.
• Iritis and iridocyclitis.
• Corneal injury from chemical burns, radiation, heat or foreign bodies.

CONTRAINDICATIONS
Hypersensitivity to dexamethasone or to any of the excipients.
Active corneal ulcer caused by herpes simplex virus.
Acute purulent infections of the eye.
Fungal infections of the eye.
UNDESIRABLE EFFECTS
The following undesirable effects may occur:

• Increased intraocular pressure.
• Glaucoma.
• Cataract formation.
• Delayed wound healing.
• Superinfection of the cornea.

PRECAUTIONS
Pregnancy and lactation
Dexamethasone 0.1% ophthalmic suspension should be used with caution during pregnancy and lactation.
Driving and operating machinery
Dexamethasone 0.1% ophthalmic suspension may cause temporary blurred vision. Patients should be cautioned about driving or operating machinery until their vision is clear.
Interactions with other medicinal products
No interactions are known.
POSOLOGY AND METHOD OF ADMINISTRATION
The recommended dose is 1-2 drops in the affected eye(s) 2-4 times daily.
Treatment should be continued for 2-3 days after the disappearance of the symptoms.
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Prolonged use of corticosteroids may increase the risk of glaucoma and cataract formation.
Patients should be monitored regularly for increased intraocular pressure during prolonged treatment.
OVERDOSE
Overdose is unlikely with ophthalmic use.
PHARMACEUTICAL PARTICULARS
List of excipients
Hypromellose, disodium phosphate, sodium phosphate, sodium chloride, purified water.
Incompatibilities
No incompatibilities are known.
Shelf life
2 years.
Storage conditions
Store in a refrigerator (2°C - 8°C).
Nature and contents of container
5 ml: Low density polyethylene (LDPE) bottle with a screw cap. The bottle contains a dropper.
Special precautions for disposal
Any unused product or waste material should be disposed of in accordance with local requirements.
Marketing Authorisation Holder
Orifarm Generics A/S
Marketing Authorisation Number
Date of first authorisation/renewal of the authorisation
Date of revision of the text
Manufactured by:
S.A.L.F. S.r.l.
info-PL orifarm.com

5/5